Madrigal Pharmaceuticals price target raised to $469 from $378 at Citi
Citi raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $469 from $378 and keeps a Buy rating on the shares post the Q4 ...
Madrigal price target raised to $405 from $400 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $405 from $400 and keeps a Buy rating on the shares ...